A recent review explored the connection between ADHD symptoms, cannabis use, the ECS, and potential therapeutic effects.
Image | adobe.stock/Phuriphat
A recently published review examined the possible connections between the endocannabinoid system (ECS) and attention deficit hyperactivity disorder (ADHD) symptoms. The review, “Attention Deficit Hyperactivity Disorder, Cannabis Use, and the Endocannabinoid System: A Scoping Review,” was published in Developmental Psychobiology in September 2024. Noting the prevalence of cannabis use and misuse in individuals with ADHD, and the lack of understanding between cannabis use and ADHD pathophysiology, researchers conducted a scoping review on preclinical and clinical evidence on the ECS and ADHD. No specific reviews have been done yet in this area, they noted.
To examine the potential therapeutic effects and influence of the ECS, researchers searched PubMed, PsyINFO, EMBASE, and the Cochrane Library for studies published up to March 2022 and examined data from relevant clinical and preclinical studies. They closely examined 13 of the studies. Data from five preclinical studies, five clinical studies examining effects of cannabis on cognition, and two clinical studies examining effects of cannabis on ADHD symptoms were presented in tables.
Data from the preclinical studies suggested that the ECS plays a role in regulating neurocognitive functions that are dysregulated in ADHD. In particular, the studies suggested:
Data from clinical studies was sparse, the researchers noted, and should be interpreted with caution. The data focused on the ECS and executive function, inhibition control and impulsivity, and ADHD symptomatology. Some of the findings from the data included:
“Findings from this review suggest both potential therapeutic benefits and detrimental drug interactions for individuals with ADHD using cannabinoids,” researchers noted in the concluding remarks. “Despite the growing popular opinion that cannabis and cannabinoids may be a therapeutic agent for ADHD symptoms, several critical questions remain unanswered. More rigorous and comprehensive studies are needed to fully understand the safety and efficacy of cannabinoid therapies in individuals with ADHD.”
The research received funding from the National Institutes of Health and two internal grants from Thomas Jefferson University.
Reference
Long-Term Cannabis Use and Cognitive Function: Findings from a Longitudinal Study
A recent study explored cannabis use and age-related cognitive decline in men, taking into account first use of cannabis and usage frequency.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Beyond THC and CBD: The Therapeutic Potential of Minor Cannabinoids in Cannabis
Here, Scott Mazza, Founder of Vitality CBD, provides an overview on the potential benefits of minor cannabinoids including cannabinol (CBN) and cannabingerol (CBG).
Croptober: The Challenges of Outdoor Cannabis Cultivation
In this segment of the cultivation education series, Adam Jacques and Zacariah L. Hildenbrand delve into croptober and the complexities that arise with outdoor, hybrid, and indoor cannabis cultivation.
Understanding Sources of Heavy Metals in Cannabis and Hemp Consumer Products, Part II: Is the Fractured Nature of State-based Regulations Ignoring the Evidence?
The second part of this column will take a look at specific examples in the public domain of elemental contamination of cannabis consumer products, which shows that other elements are worthy of consideration and should be a part of the regulatory framework.
Study from West Virginia University to investigate impact of CBD on driving performance
The five-year study will be supported by a $2.2 million grant from the National Institute of Drug Abuse.
Long-Term Cannabis Use and Cognitive Function: Findings from a Longitudinal Study
A recent study explored cannabis use and age-related cognitive decline in men, taking into account first use of cannabis and usage frequency.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Beyond THC and CBD: The Therapeutic Potential of Minor Cannabinoids in Cannabis
Here, Scott Mazza, Founder of Vitality CBD, provides an overview on the potential benefits of minor cannabinoids including cannabinol (CBN) and cannabingerol (CBG).
Croptober: The Challenges of Outdoor Cannabis Cultivation
In this segment of the cultivation education series, Adam Jacques and Zacariah L. Hildenbrand delve into croptober and the complexities that arise with outdoor, hybrid, and indoor cannabis cultivation.
Understanding Sources of Heavy Metals in Cannabis and Hemp Consumer Products, Part II: Is the Fractured Nature of State-based Regulations Ignoring the Evidence?
The second part of this column will take a look at specific examples in the public domain of elemental contamination of cannabis consumer products, which shows that other elements are worthy of consideration and should be a part of the regulatory framework.
Study from West Virginia University to investigate impact of CBD on driving performance
The five-year study will be supported by a $2.2 million grant from the National Institute of Drug Abuse.
2 Commerce Drive
Cranbury, NJ 08512
609-716-7777